Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor. The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. Asciminib was approved for medical use in the United States in October 2021, and in the European Union in August 2022.<\/p>\n
If asciminib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
SCEMBLIX (asciminib) tablets, for oral use Initial U.S. Approval: 2021<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":" Scemblix (asciminib) is a prescription medication used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).<\/p>\n DISEASE INDICATIONS-Leukemia If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201casciminib tablets\u201d based on the information you provide.<\/p>\nasciminib tablets
\nfor oral use Initial U.S. Approval: 2021<\/h2>\nFacts about asciminib tablets<\/h4>\n
\nMANUFACTURER-Novartis
\nUSAGE-Film-coated tablets: 20 mg and 40 mg
\nMEDICINE APPROVED BY-Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n